About Insitro
Insitro is a company based in San Francisco (United States) founded in 2018. Insitro has raised $643.21 million across 3 funding rounds from investors including Verily, ARE and WuXi AppTec. The company has 257 employees as of December 31, 2023. Insitro has completed 1 acquisition, including Haystack Sciences. Insitro offers products and services including insitro Platform and Therapeutic Pipeline. Insitro operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Ultragenyx, among others.
- Headquarter San Francisco, United States
- Employees 257 as on 31 Dec, 2023
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$643.21 M (USD)
in 3 rounds
-
Latest Funding Round
$400 M (USD), Series C
Mar 15, 2021
-
Investors
Verily
& 16 more
-
Employee Count
257
as on Dec 31, 2023
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Insitro
Insitro offers a comprehensive portfolio of products and services, including insitro Platform and Therapeutic Pipeline.
Integrates data to accelerate drug discovery and development processes
Focuses on metabolism, oncology, and neuroscience for new medicines
People of Insitro
Unlock access to complete
Unlock access to complete
Funding Insights of Insitro
Insitro has successfully raised a total of $643.21M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $400 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Insitro
Insitro has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include Verily, ARE and WuXi AppTec.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in technology sectors are handled by Andreessen Horowitz.
|
Locked | Locked | Locked | |
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Locked | Locked | Locked |
Investor details for Insitro
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Insitro
Insitro has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Haystack Sciences.
Investment portfolio details for Insitro
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Proprietary platform employed for small molecule drug discovery.
|
Locked | Locked | 2016 | Locked |
Complete acquisition details for Insitro
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Insitro
Detailed financials for Insitro
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Insitro Comparisons
Peer comparison for Insitro
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Insitro
Insitro operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Ultragenyx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Insitro
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Insitro
Complete news archive for Insitro
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Insitro
Insitro was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Insitro is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Insitro is a funded company, having raised a total of $643.21M across 3 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Insitro is 257.
Insitro was founded in 2018 and is headquartered in San Francisco, United States. An AI-enabled technology platform is utilized by the company to advance drug discovery and development. Focus is placed on infectious diseases such as HIV and hepatitis C, alongside cancer and genetic conditions like cystic fibrosis. Operations center on integrating machine learning with biological data to identify therapeutic targets in the biotechnology sector.
Insitro's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Insitro offers insitro Platform and Therapeutic Pipeline.
Insitro has made 1 acquisition, including Haystack Sciences.
Insitro has 17 investors. Key investors include Verily, ARE, WuXi AppTec, BlackRock, and Mubadala.